A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Pfizer
Daehwa Pharmaceutical Co., Ltd.
Orano Med LLC
Bayer
Pfizer
OncoTherapy Science, Inc.
Pfizer
CSPC Megalith Biopharmaceutical Co.,Ltd.
General Oncology, Inc.
DualityBio Inc.
OncoNano Medicine, Inc.
Ono Pharmaceutical Co. Ltd
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc.
MacroGenics
Mundipharma Research Limited
Daehwa Pharmaceutical Co., Ltd.
Leap Therapeutics, Inc.
Pfizer
Nektar Therapeutics
Protean BioDiagnostics
Kiadis Pharma
NKGen Biotech, Inc.
Incyte Corporation
Rexahn Pharmaceuticals, Inc.
Eli Lilly and Company
Sun Pharma Advanced Research Company Limited
Amwise Diagnostics Pte. Ltd.
Cellectar Biosciences, Inc.
EMD Serono
AstraZeneca
MediGene
Bristol-Myers Squibb
Bristol-Myers Squibb
Pharmacyclics LLC.
Light Sciences LLC